Tag : EASI

Abrocitinib demonstrates rapid and sustained effectiveness in treating atopic dermatitis in Chinese patients, based on AHEAD study interim findings. Over 52 weeks, significant improvements in pruritus, skin lesions, QL, and reduced economic burden highlight its value as a long-term treatment for moderate to severe AD.